本文源自智通财经网 远大中国(02789)再涨近25%，截至发稿，涨24.84%，报0.191港元，成交额1047.92万港元。 消息面上，远大中国将于8月29日召开董事会会议以审批中期业绩。公司此前预期上半年取得净利润约 1.5亿至2.1亿元，去年同期为600万元。净利增长主要原因是期间内集团国际化战略取得良好进展，海外 市场订单贡献突出，使得集团该期间的收入规模较2024同期取得增长，及该期间集团汇兑收益较2024年 同期取得增长。 国盛证券此前发布研报称，沈阳远大(远大中国)是以幕墙为主营的独立上市公司，是中国首批获准的建 筑幕墙甲级设计和壹级施工企业、国家建设部命名的建筑幕墙定点企业，是全球建筑幕墙的领军企业。 公司业务为向客户提供一站式综合幕墙解决方案，业务广泛分布全球。2024年公司中国营收10.2亿元， 占比46%，是公司业务占比最大区域；其次为美国和英国，营收均约2.4亿元，占比均约11%；卡塔尔营 收2.0亿元，占比9%。 ...

董事會會議通知 Yuanda China Holdings Limited 2789 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 遠大中國控股有限公司（「本公司」）董事會（「董事會」）謹此通知，董事會會議將於2025年8 月29日（星期五）舉行，以考慮及酌情通過（其中包括）本公司及其附屬公司截至2025年6月 30日止六個月之未經審核合併中期業績及其刊發及處理任何其他事項（如有）。 承董事會命 遠大中國控股有限公司 於本公告日期，本公司執行董事為康寶華先生、趙忠秋先生、王昊先生及張雷先生；及 本公司獨立非執行董事為王宇航先生、楊倩雯女士及哈剛先生。 主席 康寶華 中國，2025年8月15日 ...

远大中国(02789)盈喜后飙升逾60%，截至发稿，涨60.24%，报0.133港元，成交额317.44万港元。 消息面上，8月14日，远大中国发布公告，该集团预期于2025年上半年取得净利润约1.5亿-2.1亿元， 2024年同期净利润为600万元。公告称，净利增长的主要原因是该期间内集团国际化战略取得良好进 展，海外市场订单贡献突出，使得集团该期间的收入规模较2024同期取得增长，及该期间集团汇兑收益 较2024年同期取得增长。 ...

本文源自：金融界 截至2024年年报，远大中国营业总收入22.12亿元、净利润-3.54亿元。 8月14日，预计2025年中报业绩预增，溢利约1.5亿人民币至2.1亿人民币，同比增长2400%至3400%。 8月15日，远大中国(02789)盘中上涨49.4%，截至09:57，报0.124元/股，成交272.12万元。 远大中国控股有限公司是全球建筑幕墙的领军企业，主要提供高品质幕墙产品和服务，拥有超过3100个 工程项目以及6500多万平方米的幕墙，拥有1150台套先进的自动化加工设备，每年可满足1300万平方米 用户需求。公司在全球12个地区设研发机构，技术人员1500余人，研发资金占比收入的2.3到3.6%，持 续研发出新产品并获得专利授权831项。 作者：行情君 ...

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

公告称，净利增长的主要原因是该期间内集团国际化战略取得良好进展，海外市场订单贡献突出，使得 集团该期间的收入规模较2024同期取得增长，及该期间集团汇兑收益较2024年同期取得增长。 智通财经APP讯，远大中国(02789)公布，该集团预期于2025年上半年取得净利润约1.5亿-2.1亿元，2024 年同期净利润为600万元。 ...

2789 正面盈利預告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 Yuanda China Holdings Limited 股東及投資者在買賣本公司普通股份時務須謹慎行事。 承董事會命 遠大中國控股有限公司 主席 康寶華 中國，2025年8月14日 本公告乃由遠大中國控股有限公司（「本公司」，連同其附屬公司稱「本集團」）根據香港法 例第571章證券及期貨條例第XIVA部內幕消息條文（定義見香港聯合交易所有限公司證券 上市規則（「上市規則」））及上市規則第13.09(2)(a)條而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據對 本集團截至2025年6月30日止六個月（「該期間」）最新未經審核綜合管理帳目之初步評估及 董事會現時可得之其他資料，該期間本集團預期錄得淨利潤介於約人民幣150百萬元至人 民幣210百萬元，較2024年同期錄得的淨利潤人民幣約6.0百萬元有顯著改善。董事會認 為，該期間之 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 本月底法定/註冊股本總額： HKD 1,200,000,000 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 公司名稱: 遠大中國控股有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02789 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,000,000,000 | HKD | | 0.1 | HKD | | 1,200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,000,000,000 | HKD | ...

Financial Performance - Revenue for 2024 was approximately RMB 2,212.4 million, a decrease of 13.9% from RMB 2,569.5 million in 2023[12] - Adjusted gross profit margin for 2024 was 11.5%, down from 15.4% in 2023[12] - Consolidated net loss for 2024 was RMB 354.0 million, compared to a net profit of RMB 25.3 million in 2023[12] - Basic and diluted loss per share for 2024 was RMB (5.70) cents, compared to earnings of RMB 0.41 cents per share in 2023[12] - The Group's revenue and gross profit decreased in 2024 compared to 2023 due to the weak global macroeconomic conditions and unfavorable market environment[21] - The loss attributable to equity shareholders of the Company for 2024 was RMB 354.0 million, primarily due to decreased revenue and gross profit amid unfavorable market conditions[75] Cash Flow and Financial Position - Net cash generated from operating activities in 2024 was RMB 212.9 million, a decrease from RMB 349.3 million in 2023[12] - As of December 31, 2024, the Group's net current liabilities were RMB 75.1 million, a shift from net current assets of RMB 169.4 million as of December 31, 2023[80] - The Group's cash and cash equivalents increased by RMB 59.6 million or 21.7% to RMB 334.1 million as of December 31, 2024, compared to RMB 274.5 million as of December 31, 2023[82] - The total bank loans decreased by RMB 19.0 million or 2.7% to RMB 695.0 million as of December 31, 2024, from RMB 714.0 million as of December 31, 2023[83] - The gearing ratio as of December 31, 2024, was 88.7%, an increase from 82.2% as of December 31, 2023[84] Market and Economic Conditions - China's GDP in 2024 was approximately RMB 134.91 trillion, representing a 5.0% increase compared to the previous year[17] - The economic structure in China continued to optimize, indicating both quantitative growth and qualitative improvement in 2024[17] - The central government continued to implement policies to stabilize the real estate market, but overall operating pressure on real estate companies remained high due to constrained funding and high inventory levels[20] Strategic Focus and Future Plans - The company aims to focus on independent branding and intellectual property development as part of its long-term strategy[15] - The Group focused on a strategy of "cost reduction, efficiency enhancement, healthy development" in 2024 to address operational pressures[20] - In 2025, the Group plans to adopt a prudent approach in strategic decision-making and strengthen risk management measures[22] - The Group aims to capitalize on market challenges and adapt marketing strategies to evolving market dynamics in 2025[22] Operational Efficiency and Management - The Group enhanced project management efficiency and improved contract quality standards to ensure operational stability and sustainability[20] - The Group obtained 4 utility model patents in 2024, reflecting its commitment to technological innovation[38] - The Group's expected credit losses of financial and contract assets increased to approximately RMB176.8 million in 2024, up by about RMB53.2 million from RMB123.6 million in 2023, accounting for 8.0% of the Group's revenue[58] Employee and Governance Structure - The total number of full-time employees increased to 2,451 as of December 31, 2024, up from 2,376 in the previous year, reflecting the company's expansion of its technical talent pool[120] - The company has a strong management team with extensive experience in the industry, including key executives with over 29 years of experience in manufacturing and project management[123] - The company has adopted the Corporate Governance Code (CG Code) to govern its corporate governance practices, ensuring compliance with all code provisions for the year ended December 31, 2024[148] - The Board consists of seven members, including four executive directors and three independent non-executive directors, meeting the requirements of the Listing Rules[154] Diversity and Inclusion - As of December 31, 2024, the workforce consists of 2,081 male employees and 370 female employees, representing approximately 84.9% and 15.1% respectively, with a target to achieve a female employee ratio of at least 17.0% by 2030[176] - The Board has achieved gender diversity following the appointment of Ms. Yang Qianwen as an independent non-executive Director on April 18, 2023, fulfilling the requirement under Rule 13.92 of the Listing Rules[175] Risk Management - The Group plans to implement more stringent risk management measures to navigate future opportunities and challenges effectively[41] - The company has entered into forward foreign exchange contracts to hedge against foreign exchange risks from overseas projects denominated in USD, GBP, and AUD[93]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported revenue of RMB 2,212.4 million, a decrease of 13.9% from RMB 2,569.5 million in 2023[4] - The adjusted gross profit margin for 2024 was 11.5%, down from 15.4% in the previous year[4] - The company recorded a net loss attributable to shareholders of RMB 354.0 million for 2024, compared to a profit of RMB 25.3 million in 2023[4] - Basic and diluted loss per share for 2024 was RMB (5.70), compared to earnings of RMB 0.41 per share in 2023[4] - Total revenue from external customers for 2024 was RMB 2,212,363 thousand, a decrease of 13.9% from RMB 2,569,509 thousand in 2023[26] - Adjusted gross profit for 2024 was RMB 253,795 thousand, down 35.9% from RMB 396,021 thousand in 2023[28] - The company reported a pre-tax loss of RMB 248,450 thousand for 2024, compared to a profit of RMB 19,865 thousand in 2023[28] - The company recorded a consolidated net loss of approximately RMB 354.0 million for 2024, compared to a profit of RMB 25.3 million in 2023[73] Cash Flow and Liabilities - Operating cash flow generated was RMB 212.9 million, a decline from RMB 349.3 million in the prior year[4] - The company's net liabilities position shifted to RMB (75.1 million) in 2024 from a net asset position of RMB 169.4 million in 2023[11] - The company experienced a significant increase in expected credit losses on financial and contract assets, rising to RMB 176.8 million from RMB 123.6 million in 2023[5] - The group continues to negotiate with banks for the renewal of short-term loans and additional financing[13] - The company expects all trade receivables and payables to be settled within one year, maintaining liquidity[48] Revenue Breakdown - Domestic revenue for 2024 was RMB 1,016,362 thousand, a slight decrease from RMB 1,031,099 thousand in 2023[30] - Overseas revenue for 2024 was RMB 1,196,001 thousand, a decrease of 22.3% from RMB 1,538,410 thousand in 2023[30] - The total transaction value of remaining performance obligations under existing contracts as of December 31, 2024, is RMB 8,528.3 million, up from RMB 6,299.7 million in 2023[23] - The expected total transaction value of potential contracts won by the group is RMB 2,876.0 million as of December 31, 2024, down from RMB 3,558.0 million in 2023[23] Expenses and Costs - Employee costs increased to RMB 428,433 thousand in 2024 from RMB 411,524 thousand in 2023[33] - Research and development expenses rose to RMB 91,426 thousand in 2024, up from RMB 77,159 thousand in 2023[34] - The company incurred a net financing cost of RMB 68,516 thousand in 2024, compared to a net financing income of RMB 43,537 thousand in 2023[32] - The company received government grants totaling RMB 1,104 thousand in 2024, down from RMB 10,009 thousand in 2023[31] Dividends and Shareholder Returns - The company did not declare a final dividend for the fiscal year 2024, consistent with the previous year[4] - The board decided not to declare a final dividend for the year ending December 31, 2024, consistent with 2023[95] - A special dividend of HKD 0.04 per share was proposed, amounting to a total of approximately HKD 248.35 million (about RMB 229.97 million), compared to zero in 2023[52] Contracts and Projects - The total value of new contracts awarded in 2024 was approximately RMB 3,326.0 million, a decrease of about RMB 1,523.6 million or 45.8% compared to RMB 4,849.6 million in 2023, reflecting a cautious approach to project acceptance[58] - The number of projects awarded domestically decreased from 100 in 2023 to 73 in 2024, with the corresponding value dropping from RMB 2,220.6 million to RMB 1,762.1 million[59] - The total amount of uncompleted contracts as of December 31, 2024, was approximately RMB 11,404.3 million, an increase of about RMB 1,546.7 million or 15.7% from RMB 9,857.6 million in 2023, providing strong support for the company's development over the next 2-3 years[60] Auditor and Compliance - KPMG resigned as the company's auditor effective December 20, 2021, due to a disagreement over audit service fees[100] - The company appointed Daxin Hong Kong as its auditor effective December 20, 2021, but they resigned on June 17, 2022, due to the impact of COVID-19 policies[100] - KPMG was reappointed as the company's auditor effective June 30, 2022[100] - There have been no other changes regarding the company's auditors in the past three years[101] Future Outlook and Strategy - The company plans to maintain a prudent approach in strategic decisions and business operations, focusing on high-quality operations and sustainable development in 2025[63] - The company aims to enhance project management efficiency and ensure stable and sustainable operations through various measures, including refined management of individual projects and dynamic monitoring of operational risks[56]